Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma Journal Article

  

Authors:	Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; Galasso, N.; Yang, J.; Post, M.; Boardman, A.; Caron, P.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P.; Horwitz, S. M.; Intlekofer, A. M.; Johnson, W.; Kumar, A.; Lue, J.; Noy, A.; Owens, C.; Palomba, M. L.; Salles, G. A.; Steiner, R.; Stuver, R.; Vardhana, S.; Yahalom, J.; Dogan, A.; Zelenetz, A. D.; Schöder, H.; Moskowitz, A. J.
Article Title:	Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
Abstract:	PURPOSE We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).METHODSPatients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle. A geriatric assessment was performed before therapy initiation. The primary end point was progression-free survival (PFS).RESULTSPatient characteristics (N = 40) included median age of 66 years (range, 60-78 years) with 38% ≥70 years, 78% with stage III/IV disease, 68% with International Prognostic Score of ≥3, 82% dependent in ≥1 activities of daily living, 23% dependent in ≥1 instrumental activities of daily living, 50% with impaired timed up and go test, and 40% with polypharmacy. Among 37 response-evaluable patients, the median follow-up was 49 months and 3-year PFS and overall survival (OS) were 79% and 97%, respectively. Overall, 50% patients experienced grade 3/4 treatment-related adverse events (TRAEs), including febrile neutropenia in 8%. Four (10%) patients stopped therapy due to TRAEs. There was no correlation between baseline geriatric impairments and survival outcomes or toxicities. Positron emission tomography-2 was not predictive of PFS or OS.CONCLUSIONN-AVD is a highly effective and well-tolerated frontline regimen in OA with cHL across a wide range of geriatric impairments. © 2024 by American Society of Clinical Oncology.
Keywords:	aged; middle aged; clinical trial; mortality; doxorubicin; antineoplastic agent; dacarbazine; progression free survival; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; vinblastine; hodgkin disease; phase 1 clinical trial; drug therapy; geriatric assessment; progression-free survival; nivolumab; humans; human; male; female
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	8
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-03-10
Start Page:	985
End Page:	993
Language:	English
DOI:	10.1200/jco-24-01278
PUBMED:	39661923
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-86000672035&doi=10.1200%2fJCO-24-01278&partnerID=40&md5=27324753d48e6e74019fa6e5f58347a0
Notes:	Article -- MSK corresponding author is Alison Moskowitz -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/223787